Armin BREITENBACH, Claus MEESE, Hans Michael WOLFF, Roland DREWS: Transdermal delivery of (r)-3,3-diphenylpropylamin-monoestern. Schwarz Pharma, Kenyon & Kenyon, November 5, 2009: US20090274761-A1

The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C1-4alkyl, C3-10cycloalkyl, or phenyl, each of which can be substituted by C1-3alkoxy, fluoride, chlorine, bromine, iodine, nit ...

Hans Michael Wolff, Luc Quere, Jens Riedner: Novel polymorphic form of rotigotine and process for production. Harness Dickey & Pierce, June 4, 2009: US20090143460-A1

The present invention relates to a novel polymorphic form of rotigotine characterized by at least one of the following powder X-ray diffraction peaks: 12.04, 13.68, 17.72 and 19.01±0.2 (° 2θ), measured with a Cu—Kα irradiation (1.54060 Å), and a process for production thereof, which is useful for th ...

Hans Michael Wolff, Christoph Arth, Luc Quere, Walter Müller: Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine. Lohmann Therapie Systeme, UCB Pharma, December 20, 2012: US20120322845-A1

The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9: ...

JA Bouwstra, OWGMK Ackaert, J Eikelenboom, Hans Michael Wolff: Pharmaceutical composition comprising rotigotine salts (acid or na), especially for iontophoresis. UCB Pharma, April 26, 2012: US20120101146-A1

The present invention relates to new salts of 6-(propyl-(2-thiophen-2-ylethyl)amino)tetralin-1-ol (rotigotine), their use as a medicament, for example for the treatment of CNS disorders like Parkinson Disease, RLS, fybromyalgia and/or depression, in particular through electromotive administration. T ...